Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00994851
Other study ID # SENCA_L_04746
Secondary ID
Status Completed
Phase Phase 3
First received October 13, 2009
Last updated March 28, 2013
Start date September 2009
Est. completion date August 2012

Study information

Verified date March 2013
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority Brazil: National Health Surveillance Agency
Study type Interventional

Clinical Trial Summary

Primary Objective:

To evaluate the clinical efficacy of Naturetti (capsules) , considering the following criteria:

- Evacuation frequency during the treatment and follow-up period

- Consistency of stools during the treatment and follow-up period

- Global evaluation, regarding increase in frequency of evacuation and shape of stools.

Secondary Objective:

- Number of days without evacuation

- Proportion of evacuation with pain

- Proportion of evacuation with strain

- Proportion of evacuation with incomplete sensation

- Proportion of blocked stools

- Proportion of manual maneuvers to facilitate defecation

- Proportion of subjects that adhere to the diet recommended

- Proportion of the patients who have to use rescue medication

- Level of constipation improvement, according to the patient evaluation

- To evaluate clinical tolerability of the study medication by the continuous use

- To evaluate the occurrence of adverse events related to the study drug

- To identify any drug interaction.


Recruitment information / eligibility

Status Completed
Enrollment 96
Est. completion date August 2012
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 59 Years
Eligibility Inclusion criteria:

- Chronic functional constipation present, diagnosed by Rome III criteria.

- Present in most evacuations intestinal feces classified as Type 1 or 2 by the classification of Bristol.

- Women sexually active and reproductive age, using more than three months effective contraceptive method.

- Concordance, level of education and consciousness enough to cooperate with the completion of all study procedures.

- No contraindication to the use of medication in the study.

- Availability to attend all the visits of the study evaluation.

Exclusion criteria:

- History or presence of neurological disorders and / or metabolism.

- Persons with constipation caused by previous surgery.

- Presence of obstructive lesions in the gastrointestinal tract, including colorectal cancer.

- Irritable bowel syndrome or inflammatory bowel disease.

- Multiple Sclerosis

- Parkinson's disease

- Other abnormalities such as Hirschsprung's disease and Defecation Dissinrgica.

- Heart disease and / or hypertension.

- Continuous use of medication such as analgesics, anti-cholinergic (anti-histamines, antispasmodics, antidepressants, anti-psychotics), supplements with iron or aluminum, Opiates, Anti-hypertensive, CALCIUM CHANNEL BLOCKERS Preganglionic and blockers.

- Use of any other except the laxative rescue medication during the study.

- Subjects who do not confirm the diagnosis of ICFC during Phase I of the study.

- Pregnant or breast-feeding period.

- Laboratory tests outside the normal range, or the result is assessed as clinically significant by the Investigator.

- Body Mass Index (BMI) over 30.

- Participation in another clinical study within 30 days.

- Do not fill the correct Diary

- Any condition that in view of the researcher impossible the Subject to participate in the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
SENNA+CASSIA
Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
placebo
Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day

Locations

Country Name City State
Brazil Sanofi-Aventis Administrative Office Sao Paulo

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the evacuation frequency during the treatment and follow-up period 30 and 45 days No
Primary Evaluation of the stools consistency during the treatment and follow-up period 30 and 45 days No
Primary Global evaluation, regarding increase in frequency of evacuation and shape of stools 30 and 45 days No
Secondary Number of days without evacuation 30 days No
Secondary Proportion of evacuation with pain 30 days No
Secondary Proportion of evacuation with strain 30 days No
Secondary Proportion of evacuation with incomplete sensation 30 days No
Secondary Proportion of blocked stools 30 days No
Secondary Proportion of manual maneuvers to facilitate defecation 30 days No
Secondary Proportion of subjects that adhere to the diet recommended 30 days No
Secondary Proportion of the patients who have to use rescue medication 30 days No
Secondary Level of constipation improvement, according to the patient evaluation 30 days No
See also
  Status Clinical Trial Phase
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Recruiting NCT06292949 - Clinical Study of Resistant Starch in Improving Constipation N/A
Recruiting NCT04132661 - MRI Assessment of Mode of Action of Bisacodyl, Single Dose Phase 4
Terminated NCT02839889 - Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) Phase 4
Completed NCT02726295 - The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study Phase 4
Recruiting NCT02255747 - Anal Dilatation for Infants and Children With Constipation N/A
Completed NCT02246647 - Biomarkers for Intestinal Permeability in Patients With Constipation
Completed NCT01566409 - Maintenance Treatment for Children With Constipation N/A
Completed NCT01710579 - Normal Values in Ano-rectal 3D High Resolution Manometry N/A
Completed NCT02658201 - Ultrafast MRI Imaging to Exclude Constipation N/A
Completed NCT02863848 - Effect of Inulin-type Fructans on Constipated Children. N/A
Completed NCT01695915 - Diurnal Variation in Rectal Diameter N/A
Completed NCT01474499 - A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation Phase 3
Completed NCT01438567 - A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy Phase 3
Completed NCT01411501 - Efficacy and Safety of Acupuncture for Functional Constipation Phase 3
Completed NCT00931853 - Efficacy and Tolerability of Cassia Fistula Plus Senna Alexandrina Miller (Sugar Free) in the Chronic Functional Constipation (CFC). Phase 3
Completed NCT01170039 - The Effectiveness of Lubiprostone in Constipated Diabetics Phase 4
Active, not recruiting NCT02442115 - Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress
Terminated NCT01003249 - Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen Phase 4
Completed NCT01607060 - Impact of Laxative Therapy With Lactulose in the Evolution of Organ Dysfunction in Critically Ill Patients. Phase 3